Articles tagged with Prostate Cancer
A study found that PSA doubling time, pathological Gleason score, and time from surgery to biochemical recurrence are significant risk factors for prostate-specific death. Patients at high risk can be identified and offered aggressive treatment, while those at low risk can be safely observed.
A population-based case control study found that PSA screening of asymptomatic men significantly reduces the risk of metastatic prostate cancer. The researchers discovered a 35% protective effect, even among men not screened regularly.
Men with prostate cancer are 10% less likely to be working six months after diagnosis compared to those without the disease. However, approximately two-thirds of patients continue to work due to fear of losing health insurance coverage, often at reduced hours and with decreased productivity.
A new study found long-duration regular use of aspirin or NSAIDs may lower prostate cancer risk by 18%. Gene variants associated with melanoma risk were also identified in a Mediterranean population study, while another study found no link between gene mutations and response to bevacizumab
The largest study to date provides valuable insights into flexible sigmoidoscopy screening among 154,942 participants aged 55-74. Findings show that women are more likely to decline FSG than men, while non-acceptance increases with age in women. The rate of cancer detected was 2.9 per 1,000 individuals screened.
The study analyzed data from a randomized, prospective trial to determine the effectiveness of PSA testing. Researchers found that no single cutoff value would simultaneously yield high sensitivity and specificity, highlighting the need for re-education on the concept of 'normal' PSA levels.
A recent Mayo Clinic study found a significant association between benign prostate obstruction and chronic kidney disease in older men. BPH can cause bladder outlet obstruction, leading to increased risk of death, hospitalization, and cardiovascular events.
Researchers found that the GSTP1 gene is temporarily inactivated through hypermethylation, increasing the risk of prostate cancer in African-Americans compared to Caucasians. The study suggests that GSTP1 hypermethylation may serve as a potential biomarker for prostate cancer diagnosis and treatment.
Researchers found men with high sun exposure had half the risk of prostate cancer compared to those with low sun exposure. Men with certain gene variants showed a 65% reduced risk, suggesting sunlight helps reduce prostate cancer risk through vitamin D production.
A new study has shown that PET with 11C-Choline improves the early diagnosis of relapsed prostate cancer, with a sensitivity of 65% compared to 28% for conventional FDG. This finding is particularly useful for detecting relapses in patients with low PSA levels.
A study of 1500 men with locally confined prostate cancer found that delaying radiation therapy did not affect overall survival, disease-specific survival, or treatment failure rates. This research provides reassurance for patients considering delayed treatment, allowing them to make informed decisions.
Researchers have identified ERG as the first proto-oncogene commonly overexpressed in early-phase prostate cancer, providing a promising target for diagnosis and treatment. The study also found correlations between ERG expression and PSA recurrence-free survival of prostate cancer patients after radical prostatectomy.
Prostate cancer patients who have a spouse or partner report lower levels of depression and emotional distress. Support groups can also benefit single men in improving their quality of life.
A study found that men with prostate cancer who are in a relationship report better mental health, greater spirituality, and fewer urinary symptoms. The researchers conclude that clinicians should address coping mechanisms to encourage the benefits of partnership and mitigate the negative effects of being single.
Researchers found that dutasteride suppresses blood flow in benign prostate tissue, enabling targeted biopsies to detect cancer more effectively. This reduction in benign blood flow improved cancer detection rates and may reduce the need for repeat biopsies.
Researchers at Oregon Health & Science University developed a nomogram to identify men with high-grade prostate cancer and those who can be closely monitored. The chart uses clinical variables such as age, digital rectal exam findings, and PSA density to predict tumor grade, reducing the need for biopsies.
Researchers found that the combination of DN-101 and docetaxel extended overall survival by 7.1 months without increasing toxicity, outperforming docetaxel alone. Additionally, the treatment resulted in a strong PSA response, with 63% of patients experiencing a reduction in prostate-specific antigen.
Researchers have identified MMP-7 as a key player in prostate cancer-driven bone destruction, revealing a potential therapeutic target for controlling cancer-induced bone loss. The study's findings suggest that MMP inhibitors may be effective in interrupting osteolysis and promoting bone growth.
Researchers found prostate cancer in 45% of high-risk men, including those with low PSA levels. The study's findings challenge traditional screening guidelines and suggest more aggressive screening for these individuals.
A new blood test, EPCA, has been shown to be highly sensitive and specific in detecting prostate cancer. The test was found to have an accuracy rate of 94% and has the potential to reduce unnecessary biopsies and undetected tumors.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a method to expose the prostate-specific membrane antigen (PSMA) on cancer cells, making it accessible to blood-borne immunotherapies. This breakthrough could lead to more effective treatments for prostate cancer patients with advanced disease.
A study of 47,620 male health professionals found that vigorous physical activity reduced the risk of advanced and fatal prostate cancer by up to 70% among men aged 65 or older. However, no association was observed for younger men.
A study published in JAMA Network found that men with low-grade prostate cancer have a small risk of progression even after 20 years of observation or androgen withdrawal therapy. The results suggest that localized, low-grade prostate cancer patients may not require aggressive treatment.
Researchers at McMaster University are studying the connection between hormone and protein levels in prostate cancer progression. The study focuses on two proteins, PTEN and Beta-catenin, which may play a crucial role in preventing tumor formation.
The HER-2 gene has been found to play a major role in prostate cancer recurrence, according to a new study published in Cancer Research. Inhibiting the HER-2 protein may provide a novel treatment strategy for targeting advanced prostate cancer.
A clinical trial conducted by Italian scientists found that green tea catechins inhibited cancer cell growth in men with high-grade prostatic intraepithelial neoplasia, leading to a 90% efficacy rate in preventing prostate cancer. The study identified Clusterin as a key mediator of the catechins' action.
Scientists at Emory University have discovered that mitochondrial DNA variants are associated with a two-fold increase in prostate cancer risk and up to two-and-a-half times the risk for renal cancer. The U haplogroup, found among 9.6% of Caucasian Americans, is linked to an increased risk, particularly among those from northern and Ea...
A study found that inherited mitochondrial DNA variations are associated with an increased risk of developing prostate and renal cancer. Specifically, haplogroup U mtDNA was detected in higher frequencies among prostate and renal cancer patients compared to healthy individuals.
Researchers found that men who used statins had half the risk of advanced prostate cancer and a third of the risk of metastatic or fatal prostate cancer. The study suggests statins may offer benefits for preventing invasive and metastatic prostate cancer.
A study found that analyzing prostate tissue's metabolic profile can identify the biologic status of the disease, allowing clinicians to make better-informed decisions on treatment. The technique outperformed standard histopathology in differentiating between cancer cells and benign cells.
Researchers at Ludwig Institute for Cancer Research found that Smad7 protein levels may predict therapy response to 2-ME compound. The study suggests that artificially lowering Smad7 levels in prostate cancer cells reduces the compound's ability to cause cell death, leading to potential breakthroughs in personalized cancer treatment.
Researchers found that tamoxifen significantly reduced the frequency of breast enlargement and breast pain compared to radiotherapy. The study showed that tamoxifen is a more effective treatment for preventing these side effects in prostate cancer patients.
A recent study found that nearly a third of college students are overweight, while six percent are pre-diabetic. The findings suggest that early screening is crucial for preventing long-term health problems. Researchers also discovered that polyunsaturated fat intake may be linked to slower growth of prostate cancer.
A gene mutation that protects against malaria has been found to increase the risk of aggressive prostate cancer in African-American men. Researchers discovered that mice with this mutation developed larger, more aggressive tumors due to increased angiogenic chemokine production.
A new study has found that radiation therapy for prostate cancer increases the risk of developing rectal cancer by approximately 70%. The research team recommends monitoring men who have received radiation for prostate cancer starting five years after treatment.
A study published by the American Gastroenterological Association finds that radiation therapy for prostate cancer nearly doubles the risk of developing rectal cancer. Researchers recommend aggressive monitoring for men treated with radiation starting five years after treatment.
Researchers found that sociocultural and racial factors independently predicted treatment patterns in early-stage prostate cancer. Married men were more likely to receive curative treatment than unmarried men, regardless of ethnicity.
Researchers at Emory University Health Sciences Center have identified a new tumor suppressor gene, ATBF1, which inhibits cell proliferation. This finding suggests that ATBF1 may play a role in the development of prostate cancer and potentially other types of cancers.
A study found that carriers of a genetic variant associated with low antioxidant levels in the blood have a significantly increased risk of developing aggressive prostate cancer. The research highlights the potential role of antioxidants such as selenium and vitamin E in preventing prostate cancer.
A massive study is examining prostate cancer screening practices to determine their impact on death rates. The study follows 75,000 men, half of whom are screened and half receive conventional care, allowing researchers to compare survival rates.
Researchers created tumor-specific immune cells that were insensitive to TGF-beta, a powerful substance that helps cancer cells evade the immune system. These cells were able to infiltrate and destroy tumors effectively, while preventing autoimmune disease, offering new hope for treating advanced prostate cancer.
A new study found that nearly two-thirds of men are up-to-date with prostate cancer screening, but only 47.6% have had a recent colon cancer screening. The researchers suggest using prostate cancer screenings as an opportunity to encourage men to get screened for colon cancer, which is projected to affect over 70,000 men this year.
Researchers found celecoxib reduces prostate cancer cell growth and proliferation by targeting both COX-2 and cyclin D1. In animal models, celecoxib also reduced tumor mass and blood vessel density, suggesting a potential new therapeutic approach for treating prostate cancer.
Research found that hormone therapy for prostate cancer can lead to temporary declines in visual memory and recognition speed. However, cognitive function appears to be well preserved despite these changes.
The study found finasteride reduced the incidence of prostate cancer by 24.8% compared to a placebo, potentially saving thousands of lives over ten years. Despite an increase in high-grade tumors, the analysis shows that this benefit outweighs the potential drawbacks.
A new urinary marker, thymosin ß15, has been identified as a potential more accurate screening test for prostate cancer. When combined with PSA testing, it detects prostate cancer more often with fewer false-positives.
Researchers identified an inherited gene variant associated with a 50% increased risk of prostate cancer, revealing a new pathway for the disease's development. The study found that individuals carrying this variant face a higher risk of developing prostate cancer.
A study found that obesity can make prostate cancer screenings less accurate, leading to delayed diagnoses and poorer treatment outcomes. The research suggests that physicians should consider adjusting PSA values when screening for prostate cancer in overweight or obese men.
A new study found that adding more types to the current HPV DNA test would detect relatively few additional cases of cervical cancer but lead to thousands of unnecessary exams for women without cancer. Meanwhile, esophageal adenocarcinoma has increased by sixfold over the last 25 years, with no clear explanation for the rise.
Researchers found mitochondrial DNA mutations in 12% of prostate cancer samples and 7.8% of general population controls, with increased tumor growth and oxygen radical production in mutant cells. These findings suggest a causal link between mtDNA mutations and prostate cancer development, particularly in African men.
A study published in Cancer Research found that BPA exposure can lead to increased cancer cell growth in prostate cancer cells with mutated androgen receptors. This discovery has implications for men diagnosed with BPA-susceptible mutations, who may be at higher risk of cancer progression.
A Purdue University scientist has discovered that gamma-tocopherol, a form of vitamin E found in plant seeds, can inhibit the growth of prostate and lung cancer cells without harming healthy cells. The study suggests that supplementing with mixed forms of vitamin E may enhance its anticancer effects.
Researchers found that green tea polyphenols reduce levels of insulin-like growth factor-1 (IGF-1) in prostate tumor cells, leading to decreased cell survival and tumor growth. The study also showed that GTP inhibited the expression of proteins associated with metastasis and reduced vascular endothelial growth factor (VEGF) levels.
Researchers discovered that the HER2/ERBB3 pathway regulates androgen receptor function, contradicting previous beliefs about EGFR's role. This finding may explain limited success of Gefitinib, an EGFR inhibitor, in treating hormone-refractory prostate cancer.
Researchers are exploring the potential of tomato oil to reverse or delay progression of high-grade prostatic intraepithelial neoplasia (HGPIN), a precursor to prostate cancer. The study, led by Dr. Peter Gann, aims to clarify lycopene's mechanisms in the prostate and determine its chemopreventive potential.
A randomised clinical trial found that post-operative radiotherapy significantly improved biological and clinical progression-free survival in men with high-risk prostate cancer. The study showed a clear benefit in terms of biological progression-free survival for men who received radiotherapy treatment in addition to surgery.
A multi-center, double-blind study found that patients taking toremifene 20 mg had a lower cumulative incidence of cancer after 12 months, with a 48% reduction compared to placebo. High-grade prostatic intraepithelial neoplasia (PIN) is a precursor to prostate cancer.
A recent study published by the American Association for Cancer Research found that men with high-grade prostate intraepithelial neoplasia (PIN) are at a higher risk of developing invasive prostate cancer. Within one year, men in the placebo group had a 31.4% risk of being diagnosed with prostate cancer.
African-American men reported significantly higher sexual and urinary function five years after prostatectomy compared to non-Latino white men. However, they also experienced slightly more bother from changes in their function.
Researchers found that younger men and those with increased disease recurrence risk experience more frequent PSA bounces, but without additional treatment, their survival rates are comparable to those without a bounce. The large-scale study provides evidence that a PSA bounce may not automatically dictate hormone therapy.